{"id":"W4229070154","doi":"10.1016/j.annonc.2022.03.280","title":"LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Population; Breast cancer; Hazard ratio; Cancer; Randomized controlled trial; Adjuvant; Oncology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005728297,0.0003472448,0.0009344042,0.0001239196,0.0001805544,0.000007417902,0.0003622196,0.0001115139,0.0002078585],"category_scores_gemma":[0.00005291309,0.000200645,0.00009356016,0.0006109144,0.000283942,0.0001875423,0.00007246582,0.0004810395,8.358498e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002389065,"about_ca_system_score_gemma":0.000348448,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01053032,"about_ca_topic_score_gemma":0.00584239,"domain_scores_codex":[0.9968109,0.0004812425,0.0009496135,0.000519804,0.0007918478,0.0004466084],"domain_scores_gemma":[0.9973861,0.0005071397,0.0009942004,0.0005960998,0.00042989,0.00008658692],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8962827,0.006504769,0.0271697,0.0000235827,0.0007447145,0.0001165194,0.002501036,0.006403876,0.001117567,0.00008850906,0.0003178325,0.0587292],"study_design_scores_gemma":[0.4589789,0.04733578,0.4778756,0.0002031045,0.0004490132,0.00008333495,0.001141801,0.0002762233,0.0008370213,0.0003158115,0.01208211,0.0004213229],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9832212,0.0002495805,0.00001445298,0.01079066,0.0001734683,0.001933887,0.003380613,0.00003327168,0.0002028211],"genre_scores_gemma":[0.9953617,0.0001387954,0.0001189489,0.001568147,0.0001669978,0.0002872141,0.00225289,0.00004916966,0.0000561255],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4507059,"threshold_uncertainty_score":0.9960586,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03958723953281931,"score_gpt":0.3508341019965855,"score_spread":0.3112468624637663,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}